DMA names '07 pharma council chair

Share this article:
The Direct Marketing Association has named Dominque Hurley, VP and general manager for the Dendrite-owned relationship marketing firm Optas, as chairperson of its Pharmaceutical Marketing Council for 2007.

Hurley assumes sole chairperson responsibilities for the council during 2007. Last year, Hurley co-chaired the council with Commonhealth's Xchange Group's president, Nancy Barlow.

As sole chairperson, Hurley aims to increase membership from the client side, she told MM&M recently.

“I've long been a champion of the Direct Marketing Association (DMA) because I am a direct marketing person at heart and by career,” Hurley said. “I want to see the council succeed because I think pharmaceutical marketers can learn a lot from the DMA and can understand best practices, which will do so much to enhance our reputation as an industry.”

Hurley explained that the council and its membership are working to further explore the ways the group can better serve the industry.

“The DMA plays a very large role across many industries but hasn't found its footing as well as it could in the pharmaceutical arena,” Hurley said. “I am evangelizing having more events. I think the tack we are going to take is through webinars because we can make them fast and targeted and very attending to spot of the day. If we can find enough common interest in those webinars, we can create curriculum from that.”

One of Hurley's hurdles may come in gaining better representation and support from within the pharmaceutical industry.

“It's difficult to get pharma to think outside the reality of what their business challenges are,” she said. “Pharmaceutical marketers are so confined by the legislative footprint that it's very difficult to get them to look to another industry and say, ‘hmm, let me see what they've done.' I think it would be very interesting to demonstrate how best practices in other industries can be carried through in pharma. That's something I think is very important, as I lead this initiative.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...